Defining normoxia, physoxia and hypoxia in tumours - Implications for treatment response

British Journal of Radiology

Volumn 87, Issue 1035, 2014, Pages

  McKeown, S R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BANOXANTRONE; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR; OXYGEN; TIRAPAZAMINE;

ARTERIAL OXYGEN TENSION; ATMOSPHERIC PRESSURE; BLOOD OXYGEN TENSION; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; HOMEOSTASIS; HUMAN; HYPOXIA; HYPOXIC CELL; LNCAP CELL LINE; LUNG FUNCTION; NORMOXIA; OXYGEN CONSUMPTION; OXYGENATION; PHYSOXIA; RADIOSENSITIVITY; REVIEW; TISSUE OXYGENATION; TREATMENT RESPONSE; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT; ANIMAL; ANOXIA; CELL HYPOXIA; DISEASE COURSE; MALE; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; ANOXIA; CELL HYPOXIA; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASMS; OXYGEN;

EID: 84908267762     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20130676     Document Type: Review

References (126)

1. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
2. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1995; 9: 539-49.
3. Hall EJ, Giaccia A. Radiobiology for the radiologist. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
4. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82: 699-757. doi: 10.1080/09553000601002324
5. Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007; 9: 1221-35. doi: 10.1089/ars.2007.1628
6. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91. doi: 10.1038/379088a0
7. Vaupel P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol 2010; 32: 125-7.
8. Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 2011; 11: 714-23.
9. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13: 139-68.
10. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54. doi: 10.1093/jnci/djm135
11. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410. doi: 10.1038/nrc3064
12. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
13. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 2011; 15: 1239-53. doi:10.1111/j.1582-4934.2011.01258.x
14. Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. Acta Oncol 1994; 33: 383-9.
15. Becker A, Hänsgen G, Bloching M, Weigel C, Lautenschläger C, Dunst J. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998; 42: 35-41.
16. Le QT, Kovacs MS, Dorie MJ, Koong A, Terris DJ, Pinto HA, et al. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2003; 56: 375-83.
17. Falk SJ,Ward R, Bleehen NM. The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised pO2 histography. Br J Cancer 1992; 66: 919-24.
18. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12: 1507-14. doi:10.1158/1078-0432.CCR-05-2049
19. Vaupel P, Mayer A, Briest S, Höckel M. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003; 63: 7634-7.
20. Höckel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991; 51: 6098-102.
21. Kallinowski F, Buhr HJ. Can the oxygenation status of rectal carcinomas be improved by hypoxia? In: Vaupel P, Kelleher DK, Günderoth M, eds. Tumor oxygenation. Stuttgart, Germany: Gustav Fischer; 1995. pp. 291-6.
22. Kallinowski F, Buhr HJ. Tissue oxygenation of primary, metastatic and xenografted rectal cancers. In: Vaupel P, Kelleher DK, Günderoth M, eds. Tumor oxygenation. Stuttgart, Germany: Gustav Fischer; 1995. pp. 205-9.
23. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000; 48: 919-22.
24. Graffman S, Björk P, Ederoth P, Ihse I. Polarographic pO2 measurements of intraabdominal adenocarcinoma in connection with intraoperative radiotherapy before and after change of oxygen concentration of anaesthetic gases. Acta Oncol 2001; 40: 105-7.
25. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Pinover WH, Greenberg RE, et al. Hypoxia in human prostate carcinoma: an Eppendorf pO2 study. Am J Clin Oncol 2001; 24: 458-61.
26. Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 750-7. doi:10.1016/S0360-3016(03)01621-3
27. Movsas B, Chapman JD, Horwitz EM, Pinover WH, Greenberg RE, Hanlon AL, et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999; 53: 11-18.
28. Vaupel P, Thews O, Mayer A, Höckel S, Höckel M. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002; 178: 727-31. doi: 10.1007/s00066-002-1081-x
29. Vaupel P, Mayer A, Höckel M. Oxygenation status of primary and recurrent squamous cell carcinomas of the vulva. Eur J Gynaecol Oncol 2006; 27: 142-6.
30. Stone JE, Parker R, Gilks CB, Stanbridge EJ, Liao SY, Aquino-Parsons C. Intratumoral oxygenation of invasive squamous cell carcinoma of the vulva is not correlated with regional lymph node metastasis. Eur J Gynaecol Oncol 2005; 26: 31-5.
31. Lartigau E, Randrianarivelo H, Avril MF, Margulis A, Spatz A, Eschwège F, et al. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res 1997; 7: 400-6.
32. Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazolepositron emission tomography. BJU Int 2005; 96: 540-6. doi: 10.1111/j.1464-410X.2005.05681.x
33. Mattern J, Kallinowski F, Herfarth C, Volm M. Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int J Cancer 1996; 67: 20-3. doi: 10.1002/(SICI)1097-0215(19960703)67:1,20::AIDIJC5.3.0.CO;2-1
34. Winslow RM. Oxygen: the poison is in the dose. Transfusion 2013; 53: 424-37. doi:10.1111/j.1537-2995.2012.03774.x
35. Allen CB, Schneider BK, White CW. Limitations to oxygen diffusion and equilibration in in vitro cell exposure systems in hyperoxia and hypoxia. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1021-7.
36. Leach RM, Treacher DF. Oxygen transport- 2. Tissue hypoxia. BMJ 1998; 317: 1370-3.
37. Cassavaugh J, Lounsbury KM. Hypoxiamediated biological control. J Cell Biochem 2011; 112: 735-44. doi: 10.1002/jcb.22956
38. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996; 271: C1172-80.
39. Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol Apr 2010. Epub ahead of print. doi: 10.1155/2010/132641
40. Rankin EB, Giaccia AJ. The role of hypoxiainducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-85. doi: 10.1038/cdd.2008.21
41. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
42. Papandreou I, Krishna C, Kaper F, Cai D, Giaccia AJ, Denko NC. Anoxia is necessary for tumor cell toxicity caused by a lowoxygen environment. Cancer Res 2005; 65: 3171-8. doi: 10.1158/0008-5472.CAN-04-3395
43. Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, et al. Hypoxia selects for invasive, androgen independent and apoptosis-resistant LNCaP cells in vitro. Int J Cancer 2008; 123: 760-8. doi: 10.1002/ijc.23418
44. Ming L, Byrne NM, Camac SN, Mitchell CA, Ward C, Waugh DJ, et al. Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response. Int J Cancer 2013; 132: 1323-32.
45. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012; 12: 487-93. doi: 10.1038/nrc3298
46. Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335-54. doi: 10.1016/S0076-6879(04)81023-1
47. Lanzen J, Braun RD, Klitzman B, Brizel D, Secomb TW, Dewhirst MW. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res 2006; 66: 2219-23.
48. Denko N. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-13. doi: 10.1038/nrc2468
49. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2: 38-47.
50. Olive PL, Vikse C, Trotter MJ. Measurement of oxygen diffusion distance in tumor cubes using a fluorescent hypoxia probe. Int J Radiat Oncol Biol Phys 1992; 22: 397-402.
51. Torres-Filho IP, Leunig M, Yuan F, Intaglietta M, Jain RK. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci U S A 1994; 91: 2081-5.
52. Chaplin DJ, Peters CE, Horsman MR, Trotter MJ. Drug induced perturbations in tumour blood flow: therapeutic potential and possible limitations. Radiother Oncol 1991; 20(Suppl. 1): 93-101.
53. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009; 172: 653-65.
54. Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors: controversial data concerning time frames and biological consequences. Strahlenther Onkol 2012; 188: 616-27. doi: 10.1007/s00066-012-0085-4
55. Cairns RA, Hill RP. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 2004; 64: 2054-61.
56. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 2001; 61: 8903-8.
57. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13: 21-6. doi:10.1634/theoncologist.13-S3-21
58. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008; 60: 591-7. doi: 10.1002/iub.93
59. Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med 2012; 18: 534-43. doi:10.1016/j.molmed.2012.08.001
60. Semenza GL. HIF1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 2013; 123: 3664-71. doi: 10.1172/JCI67230
61. Tsai YP, Wu KJ. Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci 2012; 19: 102. doi: 10.1186/1423-0127-19-102
62. Wouters BG, Koritzinsky M. Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8: 851-64. doi: 10.1038/nrc2501
63. Koshikawa N, Maejima C, Miyazaki K, Nakagawara A, Takenaga K. Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors. Oncogene 2006; 25: 917-28. doi: 10.1038/sj.onc.1209128
64. Weinmann M, Jendrossek V, Güner D, Goecke B, Belka C. Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J 2004; 18: 1906-18. doi: 10.1096/fj.04-1918fje
65. Young SD, Hill RP. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst 1990; 82: 371-80.
66. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A.1998; 85: 9533-7.
67. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-92. doi: 10.1038/nrc2344
68. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76: 589-605.
69. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia induced metastasis. Nature 2006; 440: 1222-6. doi: 10.1038/nature04695
70. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007; 26: 333-9. doi: 10.1007/s10555-007-9063-1
71. Zhang L, Hill RP. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 2004; 64: 4180-9. doi: 10.1158/0008-5472.CAN-03-3038
72. Zhang L, Hill RP. Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion. Cancer Res 2007; 67: 7789-97. doi: 10.1158/0008-5472.CAN-06-4221
73. Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012; 3: 783. doi: 10.1038/ncomms1786.
74. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003; 20: 237-50.
75. Box C, Rogers SJ, Mendiola M, Eccles SA. Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol 2010; 20: 128-38. doi: 10.1016/j.semcancer.2010.06.004
76. Koi M, Boland CR. Tumor hypoxia and genetic alterations in sporadic cancers. J Obstet Gynaecol Res 2011; 37: 85-98. doi: 10.1111/j.1447-0756.2010.01377.x
77. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013; 23: 35-47. doi: 10.1016/j.ccr.2012.11.010
78. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012; 2: a006486. doi: 10.1101/cshperspect.a006486
79. Chang Q, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 2011; 71: 3110-20. doi: 10.1158/0008-5472.CAN-10-4049
80. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res 2012; 18: 4266-76. doi: 10.1158/1078-0432.CCR-11-3114
81. Ribatti D. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treat Rev 2011; 37: 344-52. doi: 10.1016/j.ctrv.2011.02.002
82. Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer 2008; 99: 2054-64. doi: 10.1038/sj.bjc.6604804
83. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9. doi:10.1016/j.ccr.2009.01.021
84. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31. doi: 10.1016/j.ccr.2009.01.027
85. Höckel M, Schlenger K, Höckel S, Aral B, Schäffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998; 79: 365-9.
86. Rajaganeshan R, Prasad R, Guillou PJ, Poston G, Scott N, Jayne DG. The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer. Int J Colorectal Dis 2008; 23: 1049-55. doi: 10.1007/s00384-008-0497-x
87. Movsas B, Chapman JD, Greenberg RE, Hanlon AL, Horwitz EM, Pinover WH, et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 2000; 89: 2018-24.
88. Milosevic M, Warde P, Ménard C, Chung P, Toi A, Ishkanian A, et al Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012; 18: 2108-14. doi: 10.1158/1078-0432.CCR-11-2711
89. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002; 60: 634-9.
90. Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys 2012; 82: e433-9. doi: 10.1016/j.ijrobp.2011.05.037
91. Singh RP, Franke K, Wielockx B. Hypoxiamediated regulation of stem cell fate. High Alt Med Biol 2012; 13: 162-8. doi: 10.1089/ham.2012.1043
92. Mao Q, Zhang Y, Fu X, Xue J, Guo W, Meng M, et al. A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. J Cancer Res Clin Oncol 2013; 139: 211-22. doi: 10.1007/s00432-012-1310-3
93. Ivanovic Z. Hypoxia or in situ normoxia: the stem cell paradigm. J Cell Physiol 2009; 219: 271-5. doi: 10.1002/jcp.21690
94. Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 2013; 341: 63-72. doi: 10.1016/j.canlet.2012.11.019
95. Zeng W, Wan R, Zheng Y, Singh SR, Wei Y. Hypoxia, stem cells and bone tumor. Cancer Lett 2011; 313: 129-36. doi: 10.1016/j.canlet.2011.09.023
96. Lee EK, Simon MC. From stem cells to cancer stem cells: HIF takes the stage. Curr Opin Cell Biol 2012; 24: 232-5. doi:10.1016/j.ceb.2012.01.005
97. Wion D, Christen T, Barbier EL, Coles JA. PO(2) matters in stem cell culture. Cell Stem Cell 2009; 5: 242-3. doi: 10.1016/j.stem.2009.08.009
98. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005; 104: 1129-37. doi:10.1002/cncr.21324
99. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR; Danish Head and Neck Cancer Study Group. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005; 6: 757-64.
100. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007; 25: 4066-74. doi: 10.1200/JCO.2007.12.7878
101. Jordan BF, Sonveaux P. Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front Pharmacol 2012; 3: 94. doi: 10.3389/fphar.2012.00094
102. Bennett M, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy: a systematic review of randomised controlled trials. Cancer Treat Rev 2008; 34: 577-91. doi: 10.1016/j.ctrv.2008.01.001
103. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
104. Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 2007; 69: 1008-17. doi: 10.1016/j.ijrobp.2007.04.063
105. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005; 63: 25-36. doi: 10.1016/j.ijrobp.2005.04.049
106. Leo C, Horn LC, Rauscher C, Hentschel B, Liebmann A, Hildebrandt G, et al. Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 2006; 12: 6894-900. doi:10.1158/1078-0432.CCR-06-1285
107. Joiner B, Hirst VK, McKeown SR, McAleer JJ, Hirst DG. The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse. Br J Cancer 1993; 68: 720-6.
108. Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001; 127: 346-50.
109. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3: 728-37.
110. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer:results of a phase III randomized trial. J Clin Oncol 2012; 30: 1777-83. doi: 10.1200/JCO.2011.35.9315
111. Hoskin P, Rojas A, Saunders M. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a phase II nonrandomized study. Int J Radiat Oncol Biol Phys 2009; 73: 1425-31.
112. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307. doi:10.1038/nature10144
113. Michieli P. Hypoxia, angiogenesis and cancer therapy. To breathe or not to breathe? Cell Cycle 2009; 8: 3291-6.
114. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603. doi: 10.1038/nrc2442
115. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47. doi: 10.1038/nrc1367
116. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 2007; 19: 427-42. doi: 10.1016/j.clon.2007.03.006
117. Bennewith KL, Dedhar S. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 2011; 11: 504. doi: 10.1186/1471-2407-11-504
118. Guise CP, Mowday AM, Ashoorzadeh A, Yuan R, Lin WH, Wu DH, et al. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer Jul 2013. Epub ahead of print. doi: 10.5732/cjc.012.10285.
119. Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced nonsmall-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005; 23: 9097-104. doi: 10.1200/JCO.2005.01.3771
120. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28: 2989-95. doi: 10.1200/JCO.2009.27.4449
121. Le QT, Fisher R, Oliner KS, Young RJ, Cao H, Kong C, et al. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res 2012; 18: 1798-807. doi: 10.1158/1078-0432.CCR-11-2094
122. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012; 9: 674-87. doi: 10.1038/nrclinonc.2012.171
123. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, et al. Pharmacokinetic/ pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 2010; 16: 4946-57.
124. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17: 2997-3004. doi:10.1158/1078-0432.CCR-10-3425
125. McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer 2011; 11: 432. doi: 10.1186/1471-2407-11-432
126. McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer 2012; 12: 496. doi: 10.1186/1471-2407-12-496